Strides Pharma Science Limited Asset Resilience Ratio
Strides Pharma Science Limited asset resilience ratio. Strides Pharma Science Limited (STAR) has an Asset Resilience Ratio of 0.23% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Strides Pharma Science Limited to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Strides Pharma Science Limited (2005–2026)
Asset resilience ratio of Strides Pharma Science Limited from 2005 to 2026. This chart shows how Strides Pharma Science Limited's Asset Resilience Ratio has changed over time. Read Strides Pharma Science Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Strides Pharma Science Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Strides Pharma Science Limited's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs157.86 Million | 0.23% |
| Total Liquid Assets | Rs157.86 Million | 0.23% |
Asset Resilience Insights
- Limited Liquidity: Strides Pharma Science Limited maintains only 0.23% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Strides Pharma Science Limited Industry Peers by Asset Resilience Ratio
Compare Strides Pharma Science Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
Strides Pharma Science Limited Asset Resilience Ratio by Year (2005–2026)
Strides Pharma Science Limited asset resilience ratio by year from 2005 to 2026. The table below shows the annual Asset Resilience Ratio data for Strides Pharma Science Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 0.23% | Rs157.86 Million ≈ $1.71 Million |
Rs69.27 Billion ≈ $749.15 Million |
-1.19pp |
| 2025-03-31 | 1.42% | Rs860.59 Million ≈ $9.31 Million |
Rs60.49 Billion ≈ $654.15 Million |
-0.78pp |
| 2024-03-31 | 2.20% | Rs1.29 Billion ≈ $13.90 Million |
Rs58.40 Billion ≈ $631.55 Million |
+1.34pp |
| 2023-03-31 | 0.86% | Rs572.03 Million ≈ $6.19 Million |
Rs66.38 Billion ≈ $717.92 Million |
+0.67pp |
| 2022-03-31 | 0.19% | Rs134.55 Million ≈ $1.46 Million |
Rs69.76 Billion ≈ $754.41 Million |
-1.93pp |
| 2021-03-31 | 2.12% | Rs1.49 Billion ≈ $16.12 Million |
Rs70.15 Billion ≈ $758.65 Million |
-0.57pp |
| 2020-03-31 | 2.69% | Rs1.66 Billion ≈ $17.91 Million |
Rs61.52 Billion ≈ $665.29 Million |
-2.64pp |
| 2019-03-31 | 5.33% | Rs4.27 Billion ≈ $46.14 Million |
Rs80.06 Billion ≈ $865.77 Million |
-0.05pp |
| 2018-03-31 | 5.38% | Rs3.52 Billion ≈ $38.05 Million |
Rs65.44 Billion ≈ $707.68 Million |
-10.48pp |
| 2017-03-31 | 15.85% | Rs12.87 Billion ≈ $139.15 Million |
Rs81.17 Billion ≈ $877.80 Million |
+0.09pp |
| 2016-03-31 | 15.77% | Rs12.08 Billion ≈ $130.60 Million |
Rs76.59 Billion ≈ $828.30 Million |
-6.81pp |
| 2015-03-31 | 22.58% | Rs5.61 Billion ≈ $60.70 Million |
Rs24.86 Billion ≈ $268.86 Million |
+3.46pp |
| 2014-03-31 | 19.12% | Rs4.01 Billion ≈ $43.39 Million |
Rs20.99 Billion ≈ $227.00 Million |
+19.11pp |
| 2013-03-31 | 0.00% | Rs570.00K ≈ $6.16K |
Rs47.98 Billion ≈ $518.84 Million |
-8.31pp |
| 2012-03-31 | 8.31% | Rs4.54 Billion ≈ $49.13 Million |
Rs54.64 Billion ≈ $590.93 Million |
-11.36pp |
| 2011-03-31 | 19.67% | Rs8.84 Billion ≈ $95.60 Million |
Rs44.93 Billion ≈ $485.94 Million |
+14.25pp |
| 2010-03-31 | 5.42% | Rs1.75 Billion ≈ $18.93 Million |
Rs32.30 Billion ≈ $349.29 Million |
+0.02pp |
| 2009-03-31 | 5.40% | Rs1.26 Billion ≈ $13.60 Million |
Rs23.27 Billion ≈ $251.70 Million |
-1.12pp |
| 2008-03-31 | 6.52% | Rs1.33 Billion ≈ $14.34 Million |
Rs20.33 Billion ≈ $219.91 Million |
-0.81pp |
| 2007-03-31 | 7.34% | Rs900.11 Million ≈ $9.73 Million |
Rs12.27 Billion ≈ $132.69 Million |
+1.40pp |
| 2006-03-31 | 5.93% | Rs555.41 Million ≈ $6.01 Million |
Rs9.36 Billion ≈ $101.22 Million |
-2.57pp |
| 2005-03-31 | 8.51% | Rs465.09 Million ≈ $5.03 Million |
Rs5.47 Billion ≈ $59.12 Million |
-- |
About Strides Pharma Science Limited
Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasalsprays, topical formulations, an… Read more